Status
Conditions
Treatments
About
This is a concise single arm, feasibility study, which will be executed in the University Medical Center Groningen, The Netherlands. Male patients with metastatic BC (n=6) are eligible for this study after at least 1 line of conventional endocrine therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male
A history of proven ER+ (>10% of cells), AR+ (>10% of cells), and HER2- metastatic BC
Tumor progression after at least one line of conventional endocrine therapy (tamoxifen, AI, fulvestrant, CDK4/6, ±LHRH analogue).
Age ≥ 18 years
Adequate hematological, renal and liver function as follows:
Written informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
5 participants in 1 patient group
Loading...
Central trial contact
Geke A.P Hospers, MD,PhD; Jasper J.L. van Geel, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal